Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1306
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
TRUVADA (Tablet, Film Coated)
|
| dailymed-instance:activeIng... | |
| dailymed-instance:boxedWarn... |
WARNINGS: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA, in combination with other antiretrovirals [See Warnings and Precautions (5.1)]. TRUVADA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of TRUVADA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue TRUVADA. If appropriate, initiation of anti-hepatitis B therapy may be warranted [See Warnings and Precautions (5.2)].
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:Croscarmellose_Sodium,
dailymed-ingredient:FD&C_Blue_#2_Aluminum_Lake,
dailymed-ingredient:Hydroxypropyl_Methylcellulose_2910,
dailymed-ingredient:Lactose_Monohydrate,
dailymed-ingredient:Magnesium_Stearate,
dailymed-ingredient:Microcrystalline_Cellulose,
dailymed-ingredient:Opadry_II_Blue_Y-30-10701,
dailymed-ingredient:Pregelatinized_Starch,
dailymed-ingredient:Titanium_Dioxide,
dailymed-ingredient:Triacetin
|
| dailymed-instance:genericMe... |
emtricitabine and tenofovir disoproxil fumarate
|
| dailymed-instance:fullName |
TRUVADA (Tablet, Film Coated)
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
TRUVADA
|